These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 15598977

  • 1. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
    Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P.
    J Clin Oncol; 2005 Feb 10; 23(5):990-8. PubMed ID: 15598977
    [Abstract] [Full Text] [Related]

  • 2. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
    Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS.
    J Clin Oncol; 2000 Feb 10; 18(4):716-23. PubMed ID: 10673512
    [Abstract] [Full Text] [Related]

  • 3. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
    Cattelan AM, Calabrò ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, Gasperini P, Zanchetta M, Cadrobbi P, Monfardini S, Chieco-Bianchi L.
    Int J Oncol; 2005 Sep 10; 27(3):779-85. PubMed ID: 16077928
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
    Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM.
    J Clin Oncol; 2006 Mar 20; 24(9):1389-94. PubMed ID: 16549833
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
    Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U, AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals.
    J Clin Oncol; 2003 Aug 01; 21(15):2876-82. PubMed ID: 12885804
    [Abstract] [Full Text] [Related]

  • 10. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.
    Gill PS, Lunardi-Ishkandar Y, Louie S, Tulpule A, Zheng T, Espina BM, Besnier JM, Hermans P, Levine AM, Bryant JL, Gallo RC.
    N Engl J Med; 1996 Oct 24; 335(17):1261-9. PubMed ID: 8857005
    [Abstract] [Full Text] [Related]

  • 11. [AIDS-associated Kaposi's sarcoma: 22 cases].
    Dhrif AS, Kilani B, Ammari L, Kanoun F, Tiouri H, Ben Chaaben T.
    Tunis Med; 2007 Jun 24; 85(6):494-9. PubMed ID: 17644904
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
    Pellet C, Chevret S, Blum L, Gauvillé C, Hurault M, Blanchard G, Agbalika F, Lascoux C, Ponscarme D, Morel P, Calvo F, Lebbé C.
    J Invest Dermatol; 2001 Oct 24; 117(4):858-63. PubMed ID: 11676823
    [Abstract] [Full Text] [Related]

  • 14. Regression of AIDS-related Kaposi's sarcoma following combined antiretroviral treatment.
    Monticelli A, Lewi D, Salomon H, Pampuro S, Libonatti O, Jauregui Rueda H, Hodara V.
    Rev Argent Microbiol; 2000 Oct 24; 32(4):206-8. PubMed ID: 11149154
    [Abstract] [Full Text] [Related]

  • 15. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
    Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM.
    J Clin Oncol; 2005 Feb 20; 23(6):1253-60. PubMed ID: 15718323
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.